• We evaluated the Friedewald Equation and three other recently developed formulae.
Introduction
LDL-cholesterol (LDL-C) is used for cardiovascular disease (CVD) risk assessment [1, 2] . The gold standard for measurement of LDL-C is by ultracentrifugation and betaquantification [3] . This is expensive and inconvenient for the routine laboratory. Other methods include direct measurement of LDL using a homogeneous assay, but this is too expensive for use in most laboratories.
Furthermore, direct methods show poor performance with high triglyceride (TG) levels [4] [5] [6] . An earlier review comparing direct measurement of LDL-C vs calculation of LDL recommended the use of direct LDL measurements in hypertriglyceridaemic patients [6] . However, a recent study comparing eight direct measurements of LDL-C and HDL-C failed to show improved CVD risk classification of most direct methods over calculated LDL-C [4] .
The first formula to calculate LDL-C was developed over 40 years ago by
Friedewald [7] . The formula requires fasting plasma high density lipoproteincholesterol (HDL-C), total cholesterol (TC), and TG, and is calculated as LDL-C = TC -HDL -(TG/5) for mg/dl (2.2 in mmol/l). This formula is less accurate in extremes of TG or TC values [7] [8] [9] [10] or in patients with co-morbidities (eg. renal failure or diabetes) [2, 11] , but is widely used. Several other formulae have been developed, but these did not perform better than Friedewald's calculation [12] [13] [14] or had varying results in different population groups [10, [15] [16] [17] [18] [19] and including those considering TG ratios [20, 21] . In the latest study validating a novel formula in comparison with Friedewald's calculation and the LDL-C reference method in 23 055 patients, the benefits over
Friedewald were not considered substantial enough to replace its use in clinical practice [22] , demonstrating positive bias at low levels of LDL (<1.81 mmol/L). The previously published formula by de Cordova et al [23] has been reported to outperform several of the earlier LDL-C formulae, including Friedewald's formula, over a wide-3 range of lipid levels using the equation LDL-C = 0.7516 (TC -HDL-C) in 10,664
Brazilian patients, including those with co-morbidities. However, this formula also showed bias at low levels of LDL-C in a subsequent study of 576 healthy subjects in South Africa [24] .
As difficulties with LDL measurements prevail, a search for new formulae and emerging cardiovascular risk markers to improve accurate CVD prediction is ongoing.
We validated the application of four formulae (Friedewald, de Cordova, Chen, Hattori) to calculate LDL-C in our population of hospitalized patients. We compared the formulae to the direct measurement of LDL-C, using the largest sample size to date, where multiple formulae are compared.
Methods

Study population
This was a retrospective evaluation of lipid profiles in 14, 219 patients in South Africa, Blood samples were collected into serum separator tubes to determine LDL-C, HDL-C, TG and TC. Samples were centrifuged after collection and analysed immediately.
Patient details were anonymized, with only patient age and gender reported. 4 Measurements of LDL-C, HDL-C, TC and TG were performed using reagents by Beckman Coulter, according to the specification of the manufacturers using the Beckman DXC automated analyser (Brea, CA, USA).
The direct LDL-C method is a homogeneous assay without the need for any pretreatment or centrifugation steps and based on the Daiichi two-phase method [25] .
The coefficient of variation (CV) of LDL-C using the homogenous method was 4.5%
for level 1 and 4.0% for level 3.
The HDL-C measurement was performed using a homogenous, colorimetric, enzymatic method. The CV of the HDL level 1 and 3 respectively was 6.3% and 4.3%. Total cholesterol measurement involved a colorimetric, enzymatic, timedendpoint method; the CV of the TC at level 1 and 3 were 3.4% and 4.6% respectively.
Triglyceride measurement used a sequence of three coupled enzymatic steps to form a red quinoneimine dye. The CV of the TG measurements at level 1 and 3 were 4.3% and 3.9% respectively. The performance standards in terms of the CV for the lipid analysis were all within the acceptable CV for Beckman DxC800.
Data Analysis
Microsoft Excel was used to capture the data, according to the different lipid levels and for the calculation of LDL-C. STATA was used to perform the statistical analysis, which included a descriptive statistics summary. Pearson's correlation was performed for directly measured LDL-C and non-HDL-C, as well as between the four formula and 
Results
A total of 14,219 lipid profiles were identified, of which 39% were male and 61% were Using Pearsons analysis, we show high correlations between the four formulae and directly measured LDL-C using the Daiichi two-phase method (Table 1 Table 2 . bias the lower the LDL-C level using the de Cordova formula, as shown in their study [24] . The other three formulae showed a more uniform distribution of points with the Bland-Altman plots, making the bias observed with these formulae more predictable than the de Cordova formula. We compared the accuracy between four formulae in calculating LDL-C, and found that the Hattori formula performed best across a range of lipid values in a large database of hospitalized patients. [7] , in patients with renal [27] and liver [28] disease, and those with diabetes mellitus [11] and other metabolic conditions [29] . The Friedewald formula cannot be used in non-fasting samples as it does not consider the cholesterol formed post-prandially in chylomicrons [30] ; thus these levels were not part of the original data set [7] . The de Cordova formula is the most recently published formula and reports better accuracy than the Friedewald in calculating LDL-C [23] . However, a subsequent analysis of 597 healthy subjects showed better agreement of the Friedewald formula with a directly measured LDL-C [24] . Another recent study compared four formulae in 164 subjects including those with dyslipidemias and co-morbidities and found that the Friedewald equation had the best overall performance for calculating LDL-C [33] .
These studies did not compare the Friedewald with the Hattori formula.
In the calculation of LDL-C, three measurements are usually used, including TC, HDL-C, and TG. Therefore, the accuracy of calculated LDL-C can be affected by errors from any of these measurements. The aforementioned study also compared calculated LDL-C formulae with 8 directly measured HDL-C assays using homogenous methods and demonstrated that the optimum equation for calculating LDL-C depends on which direct HDL-C assay is used [33] . It was shown that the Daiichi 2-phase method used in our study to measure HDL-C had the third lowest 12 percentage misclassifications using the Friedewald formula, and the second lowest with the Chen formula in a recent study comparing eight HDL-C assays. Use of different TC and TG methods is not as likely to significantly affect the calculation of LDL-C as much as direct HDL-C assays because of the better standardization of TC and TG. The TC and TG methods used in our study also differed from their respective reference methods by less than 2%.
We confirm previous findings that the Friedewald formula's performance decreases with increasing TG levels [23] , and demonstrate that it performed most poorly at the lowest TG levels. The Friedewald formula was previously shown to incorrectly estimate LDL-C at the lowest TG levels [8, 10] de Cordova (Wako) [33] .
The limitations of our study include the fact that racial origins were not specified and could not be considered in the analysis. However, the database is from a large hospitalized population representative of the various ethnic origins in South Africa.
Secondly, although we used a non-reference method for the measurement of LDL-C, as with two similar previous analyses [23, 24] , our methods meet the NCEP standards of precision. Although we were unable to evaluate the formulae by disease categories,
we had a large sample size with varying lipid ranges. We were thus able to consider the effect of the four formulae at high and low TG values, similarly to the de Cordova study. Another limitation is that we focused only on four LDL-C calculations, using the most recently published [23] , most widely used [7] and two formulae previously confirmed in a large database to perform well in extreme lipid values [16, 17, 23] , as seen in our hospitalized study sample. The samples we analyzed were from hospitalized patients and the findings cannot be generalized to the general population.
However, we do report these analyses on the largest database to date -14,219
patients. Although patient-specific data about presence/absence of disease, treatments and ethnicity was not available, our database of hospitalized patients is 14 representative of those with diabetes, dyslipidemia and other metabolic conditions and co-morbidities.
Formulae have reported poorer performance in low-and high TG values, and it has been suggested to use direct measurements of LDL-C instead of calculations in hypertriglyceridaemic samples [4, 33] . Measurements of LDL-C are further complicated by LDL-C being a multiple molecular particle aggregate of protein, cholesterol and other lipids [34] . Normal LDL-C is often observed in myocardial infarction, but with increased LDL-apolipoprotein B (Apo B) [17, 35] . It is these small dense LDL particles that are more highly correlated with CVD, rather than the concentration of particles present [36] . The contribution of these aggregates is not fully considered in the existing formulae to calculate LDL-C. In a prospective study of 2222 men free from ischaemic heart disease (IHD), correction of the Friedewald formula to account for Lp(a) levels (the Dahlen modification) did not improve the evaluation of IHD risk [37] . One recent study considered the variance in the TG:Very low density lipoprotein cholesterol (VLDL-C) ratio, and found that using a 180 panel specific to TG and HDL-C levels improves the accuracy of their formula (non-HDL-C -TG/adjustable factor mg/dL) as compared to Friedewald [21] . However, a subsequent validation study found uncertainties in both this novel formula and Friedewald at low LDL-C levels (<1.18 mmol/l) [22] . Accuracy of the formulae may be improved where TG/VLDL-C ratios are taken into consideration [21] , particularly in hypertriglyceridaemic patients. The authors found that most of the variance in the ratios could be explained by TG and non-HDL-C levels. The latter observation could further explain the differences in performance of the formulae, as the Chen formula
equates LDL-C to 90% of non-HDL-C plus 10% of triglycerides, whereas de Cordova takes 75% of non-HDL-C and Hattori 94% of non-HDL-C.
Debate thus exists on whether two alternative markers -non-HDL-C (the sum of masses of cholesterol in the Apo B lipoprotein particles) and Apo B (the main apoprotein of atherogenic lipoproteins) should supplant LDL-C in CVD risk calculations. At present, there exists insufficient evidence to warrant this substitution [38] . However, the markers may provide additive value to CVD risk assessment [39] .
We have demonstrated that LDL-C and TC correlate highly with non-HDL-C, as shown previously [23] . Recent reviews have established the superiority of non-HDL-C and ApoB over LDL-C in predicting CVD risk in epidemiological studies [35] and in randomized trials of patients on statin treatment [40] . Non-HDL-C has been recommended by previous ATP III guidelines as a secondary target of therapy and to be used to assess risk in patients with elevated TG levels [>200 mg/dl (>2.26 mmol/l)] [1, 2] , with the latter confirmed by a subsequent study comparing non-HDL-C to direct and calculated LDL-C using 8 different assays [4] . In terms of clinical practice, revised guidelines by the AHA report no additional mortality benefit to further treat non-HDL-C levels once an LDL-C goal is reached [26] . Concerns also exist about the reliability of non-HDL-C measurements, as a result of problems with direct HDL-C measurements [29] . Alternatively, Apo B and its association with CVD risk have been recognized [39, 40] , reportedly performing better than LDL-C in hypertriglyercedaemic patients [35, 41] and as an index of LDL-lowering therapy [39] . The Hattori formula for LDL-C (0.94TC -0.94HDL-C -0.19 x TG) was developed to estimate LDL-Apo B and small dense LDL from blood cholesterol, TG, HDL-C and in this way be more accurate in patients with cardiovascular co-morbidities and dyslipidemias. Unlike the Friedewald formula, the Hattori formula excludes IDL to provide a more accurate estimate of LDL-C. The estimation of lipid particles in the Hattori formula may explain why that particular formula performs best across various TG, HDL and TC levels in our hospitalized 16 population. Formulae that incorporate Apo B or non-HDL-C measurements may be of interest in pursuing LDL-C calculations to predict CVD risk.
Conclusions
In conclusion, we confirm recent findings that the Friedewald formula has a better agreement with directly measured LDL-C based on the Daiichi method compared with the agreement with the de Cordova [23] , but not at low TG values in a large hospitalized population. Furthermore, we show that neither the Friedewald or de
Cordova formula perform as well as the Chen or Hattori formula in this population group.
Competing interests
The authors have no conflicts of interest. 
Supplementary Figures
